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Abstract
Matrix metalloproteinase-9 (MMP-9) produced by tumor cells is known to be implicated in the invasion of squamous cell
carcinoma (SCC). In the process of searching for agents to inhibit MMP-9 in cancer, immunosuppressive factors,
dexamethasone (DEX) and interleukin-4 (IL-4) were found to inhibit protein production as well as gene expression of MMP-
9 in tumor necrosis factor K (TNFK)-stimulated SCC cells. DEX and IL-4 could also suppress the expression of urokinase
type plasminogen activator (uPA) to prevent the conversion from the proenzyme form of MMP-9 to its active form.
Regarding their mechanisms to inhibit the expression of MMP-9 and uPA, DEX and IL-4 had no effect on the cell surface
levels of TNFK receptors, but inhibited the activation of NF-UB and NF-UB-dependent gene expression. DEX, but not IL-4,
could strongly augment the TNFK-induced expression of IUBK in SCC cells. These results suggest that DEX and IL-4
suppress not only immunological reactions, but also tumor invasion by targeting NF-UB. ß 2002 Elsevier Science B.V. All
rights reserved.
1. Introduction
It is well known that matrix metalloproteinases
(MMPs), secreted from either tumor cells or stromal
cells, are involved in cancer invasion and metastasis
by degrading extracellular matrices [1]. Especially,
MMP-2 and MMP-9 can break down basement
membranes containing type IV collagen, which is
an initial step in cancer invasion. Indeed, high levels
of MMPs have been detected in a variety of tumors
including oral, head and neck cancer [2^4]. Some
MMPs such as MMP-9 are released from epithelial
tumor cells while some MMPs including MMP-2 are
synthesized by the stromal cells adjacent to tumors
[5].
Other evidence showing the MMP involvement in
the tumor behaviors has come from knockout mice
experiments [6]. Transplanted epithelial tumor cells,
which easily metastasize to the lungs in control mice,
could not metastasize in MMP-2 knockout mice,
thus showing that the MMP-2 expression of stromal
cells plays an important role in the metastasis of the
epithelial tumor cells [6].
In general, MMPs are secreted as their proenzyme
form from cells, which are then activated by the
proteolytic cleavage of their N-terminal part [1].
This conversion to an active form is mediated by
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other proteases, mainly urokinase type plasminogen
activator (uPA) [7], stromelysin (MMP-3) [8] or
membrane type MMPs (MT-MMPs) in the case of
MMP-2 [9].
From this evidence, MMP inhibitor is expected to
inhibit tumor invasion and metastasis. Indeed, a syn-
thetic MMP inhibitor has been developed and ad-
ministered in clinical trials, recon¢rming that
MMPs play an important role in tumor behaviors
[10].
In order to regulate tumor invasion, therefore, it is
very critical to understand and control the intracel-
lular signaling molecules, especially transcription fac-
tors, leading to MMP gene expression.
NF-UB is a transcription factor involved in a vari-
ety of gene expressions [11] including MMP-9 [12]
and uPA [13]. The latent form of NF-UB is a com-
plex of p50 (NF-UB1), p65 (RelA) and an inhibitor
called IUB, and resides in the cytoplasm. Such cell
stimulators as tumor necrosis factor K (TNFK), in-
terleukin-1 (IL-1), free radicals and UV radiation
activate IUB kinases to phosphorylate the serine res-
idues in a IUB molecule. A phosphorylated IUB is
then ubiquitinated and proteolyzed by a cytosolic
ATP-dependent protease complex, 26S proteasome.
Degradation of IUB releases NF-UB (p65-p50 hetero-
dimer), which in turn translocates into the nucleus
and binds to the speci¢c DNA sequence to trigger
the transcriptions of the target genes which are
mainly involved in in£ammation [11].
We have previously reported that pretreatment
with synthetic proteasome inhibitors suppressed
NF-UB activation, MMP-9 expression and cell mi-
gration of oral squamous cell carcinoma (SCC) cells,
implying that a shuto¡ of the signaling pathway
leading to MMP-9 expression contributes to the in-
hibition of tumor invasion [14]. In this context, it is
important to explore the factors or agents capable of
inhibiting the expression of MMP-9 in tumors. Be-
cause the molecular events occurring in tumor inva-
sion resemble those in wound healing processes, trig-
gered by in£ammatory or immunological reactions
[15], immunosuppressive or anti-in£ammatory fac-
tors should be studied for their potential in tumor
control.
In the present study, we examined the e¡ects of
two immunosuppressive factors, dexamethasone
(DEX) and interleukin-4 (IL-4) on the expression
and activation of MMP-9 in oral SCC cells. DEX
and IL-4 were able to inhibit the expressions of
MMP-9 and uPA. In the mechanism by which
they inhibit the gene expressions of MMP-9 and
uPA, DEX as well as IL-4 suppressed NF-UB acti-
vation in SCC cells. The MMP-9-dependent inva-
sion of SCC in oral cavity, head and neck may be
inhibited by DEX and IL-4 through their e¡ects on
NF-UB.
2. Materials and methods
2.1. Reagents
Rabbit polyclonal antibodies against human IUBK,
NF-UB p65 and NF-UB p50, and monoclonal anti-
body against human glucocorticoid receptor (GR) K
were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Monoclonal antibodies against
human 55 kDa TNF receptor (TNF-R1) and 75
kDa TNF receptor (TNF-R2) were obtained from
RpD systems (Minneapolis, MN). Monoclonal anti-
body against human MMP-9 was purchased from
Oncogene Science (Uniondale, NY). Monoclonal
antibody against human uPA was from American
Diagnostica (Greenwich, CT). Recombinant human
TNFK was kindly provided by Dainippon Pharma-
ceuticals (Tokyo, Japan). DEX was provided by Sig-
ma (St. Louis, MO). Recombinant human IL-4 was
purchased from Genzyme (Cambridge, MA). Human
puri¢ed plasmin was obtained from Enzyme Re-
search Laboratories (South Bend, IN). Recombinant
human IL-10 was kindly given by Dr. Takeshi Otsu-
ka, Department of First Internal Medicine, School of
Medicine, Kyushu University. Human puri¢ed plas-
minogen was purchased from Sigma. A synthetic hy-
droxamic acid-based MMP inhibitor KB-R8301 and
its non-active control KB-R8845 were kindly do-
nated from Dr Kouichiro Yoshino, Kanebo Insti-
tute, Osaka, Japan [16]. Both KB-R8301 and KB-
R8845 were dissolved in dimethyl sulfoxide
(DMSO) to make a 10 mM stock solution.
2.2. Cell culture
Oral SCC cell lines, SAS [17], NA, Ca9^22, HSC-
2, HSC-3, TF, and KN, which were all established
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from oral SCC lesions, were cultured in a Dulbecco’s
modi¢ed Eagle’s medium (DMEM) containing 10%
fetal bovine serum. For the assay, con£uent cells
were incubated with or without reagents in a se-
rum-free DMEM for 24 h before either collecting
the conditioned media or preparing the cell extracts.
Usually, the treatment with DEX or IL-4 started 1 h
prior to the addition of TNFK.
2.3. Cell migration assay
A modi¢ed Boyden chamber was used for the cell
migration assay [14]. Cell culture inserts, each with a
bottom consisting of a polyethylene terephthalate
track-etched membrane with an 8.0 Wm pore size
and a diameter of 6.4 mm (Falcon, Nippon Becton
Dickinson, Tokyo, Japan), were coated with 10 mg
gelatin and then put in wells containing 700 Wl of
serum-free DMEM. The gelatin-coated membrane
separated an upper chamber from a lower chamber
in each well. Detached cells (3U105 cells in 200 Wl of
serum-free DMEM) were inoculated into the upper
chamber. TNFK was then added to the lower cham-
ber. After 24 h culture, the cells attached to the
upper surface of the membrane were scraped o¡,
and the cells migrating onto the lower surface were
¢xed and stained. The migration activity was deter-
mined by averaging the number of cells that had
migrated in four high-power ¢elds under a micro-
scope [14].
2.4. Zymography
Serum-free conditioned medium was collected
from a con£uent culture of oral SCC cells incubated
in the presence of reagents for 24 or 48 h. The con-
ditioned media were resolved by 10% sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) in the presence of 1 mg/ml gelatin. The ap-
plied amounts of each medium were standardized to
the total protein levels of cultured cells. The resulting
gel was washed in 10 mM Tris (pH 8.0) containing
2.5% Triton X-100, and was then incubated for 16 h
in a reaction bu¡er (50 mM Tris (pH 8.0), 0.5 mM
CaCl2, 1036 M ZnCl2) at 37‡C. After staining with
Coomassie brilliant blue R-250, gelatinases were
identi¢ed as clear bands of lysis against a blue back-
ground [14].
2.5. Western blot analysis
For MMP-9 and uPA detection, the conditioned
media were separated in 10% SDS^PAGE and trans-
ferred electrophoretically to polyvinylidene di£uoride
membrane (Nihon Millipore, Tokyo, Japan). The ap-
plied amounts of each medium were standardized to
the total protein levels of the cultured cells. The
membrane was incubated for 1 h with anti-MMP-9
or anti-uPA antibody after blocking with 5% (w/v)
dried milk solution. The bound antibodies were then
visualized by a peroxidase reaction using biotinylated
goat anti-mouse IgG and an avidin^biotin complex
kit (Vector, Burlingame, CA). For IUBK or p65 de-
tection, the cytosols of SAS cells were separated in
12% SDS-polyacrylamide gel, and rabbit anti-IUBK
or anti-p65 antibody and biotinylated goat anti-rab-
bit IgG were used as the primary and secondary anti-
body, respectively.
2.6. Electrophoretic mobility shift assay
Nuclear extracts were prepared following the
method described by Guesdon et al. [18]. The se-
quence of the NF-UB binding oligonucleotide used
as a radioactive DNA probe was 5P-AGCTTGGG-
GACTTTCCGAG-3P. The DNA binding reaction
was performed at room temperature in a volume of
20 Wl, which contained the binding bu¡er (10 mM
Tris^HCl (pH 7.5), 1 mM EDTA, 4% glycerol, 100
mM NaCl, 5 mM dithiothreitol, 100 mg/ml bovine
serum albumin), 3 Wg of poly(dI-dC), 1U105 cpm of
32P-labeled probe, and 5^10 Wg of nuclear proteins.
After incubation for 15 min, the samples were elec-
trophoresed on native 5% acrylamide, 0.25U Tris
borate^EDTA gels. The gels were dried and analyzed
by a Fujix BAS 2000 bioimage analyzer (Fuji, To-
kyo, Japan) [19].
2.7. Reverse transcriptase^polymerase chain reaction
(RT^PCR) analysis
The total RNA was extracted from the cultured
cells with TRIzol (Life Technologies, Gaithersburg,
MD). cDNA was synthesized from 3 mg of RNA
with random hexamer primers (Promega, Madison,
WI) and RT (BRL, Gaithersburg, MD). Five percent
of the ¢rst-strand cDNA pool was submitted to PCR
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ampli¢cation using gene-speci¢c PCR primers by
standard PCR protocols. The oligonucleotide prim-
ers for MMP-9 were 5P-GTGCTGGGCTGCTGCT-
TTGCT-3P and 5P-GTCGCCCTCAAAGGTTTGG-
AA-3P. The primers for the IL-4 receptor K chain
were 5P-ATGGGGTGGCTTTGCTCTGGG-3P and
5P-GGGCTTGAAGGAGCCCTTCCA-3P. The
primers for uPA were 5P-AGAATTCACCACCACC-
GAGA-3P and 5P-ATCAGCTTCACAACAGTCAT-
3P. The PCR program was as follows: 30 cycles at
96‡C for 30 s, 67‡C for 30 s, and 72‡C for 45 s. The
PCR products were separated by electrophoresis on
1.8% agarose gels and were then visualized by ethid-
ium bromide staining with ultraviolet light illumina-
tion.
2.8. Northern blot analysis
The cell RNA was fractionated on a 1% agarose
gel containing 0.66 M formaldehyde, transferred
onto a nylon membrane (Nytran-N, Schleicher and
Schuell, Dassel, Germany) and UV cross-linked at
0.25 J/cm2 using Fluolink (Viler Lourmat, Marne-
La-Vallee, France). The membrane was hybridized
to 32P-labeled DNA probes in Hybrizol (Oncor, Gai-
thersburg, MD) at 42‡C for 24 h and was then
washed twice at room temperature in 2U SSC (1U
SSC is 0.15 M NaCl plus 0.015 M sodium citrate)
and 0.1% SDS, once in 1U SSC and 0.1% SDS and
once more in 0.2U SSC and 0.1% SDS. The mRNA
levels were quanti¢ed by densitometry with a Fujix
BAS 2000 bioimage analyzer (Fuji, Tokyo, Japan).
2.9. Immunoprecipitation
The cell lysates for immunoprecipitation were pre-
pared by treating the cells with immunoprecipitation
bu¡er (50 mM Tris^HCl (pH 7.4), 150 mM NaCl,
1% (w/v) Triton X-100, 1 mM Na3VO4, 50 mM
NaF) freshly supplemented with 1 mM PMSF,
Fig. 1. TNFK-enhanced production of MMP-9 from SCC cells. Seven SCC cell lines were cultured to subcon£uency and treated for
24 h with or without TNFK (100 ng/ml). MMP-9 in the conditioned media from each cell line was analyzed by gelatin zymography
(A) and Western blotting (B). A 92 kDa molecular size indicates the proenzyme form of MMP-9.
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2 Wg/ml leupeptin, 1 Wg/ml pepstatin A. The resulting
lysates were incubated with anti-glucocorticoid re-
ceptor (GR) antibody or anti-p65 antibody for 2 h
and then mixed with 50 Wl of protein G^Sepharose
(Santa Cruz, CA) for 1 h. After centrifugation of
reaction mixtures, the pellets were washed with im-
munoprecipitation bu¡er, dissolved in 2U Laemmli’s
bu¡er without 2-mercaptoethanol, and then centri-
fuged again. The supernatant was immunoblotted
with anti-p65 antibody or anti-GR antibody.
2.10. Flow cytometric analysis
The cultured SAS cells were detached from the
plastic culture dishes after being treated with 0.05%
trypsin including 0.53 mM EDTA. Single cell suspen-
sions were stained with non-immune serum or anti-
TNF receptor antibody for 30 min at 4‡C. FITC-
conjugated goat anti-mouse IgG antibody was used
as a second antibody. Twenty thousand gated cells
were analyzed on a FACSort (Becton Dickinson,
Mountain View, CA).
2.11. Assay for uPA activity
uPA activity was measured using the plasmin-spe-
ci¢c chromogenic substrate S-2251 [20]. In this assay,
50 Wl of serum-free conditioned medium was incu-
bated with 50 Wl of S-2251 (1.5 mM) and 50 Wl of
plasminogen (60 Wg/ml) at 37‡C in £at-bottomed mi-
crotiter plates. The release of paranitroaniline from
S-2251 was determined in each well by measuring
absorbance at 405 nm using a microplate reader.
2.12. Luciferase assay
SAS cells (1U106) were incubated with 2 Wg
pNFUB-Luc plasmid, an NF-UB-dependent lucifer-
ase reporter construct (Stratagene, La Jolla, CA)
and 4 Wl lipofectAMINE reagent (Life Technologies,
Grand Island, NY) in serum-free DMEM for 5 h.
After the addition of fetal calf serum to a ¢nal con-
centration of 10%, the transfected cells were treated
with DEX or IL-4, prior to the addition of TNFK.
After 3 or 6 h incubation, cell lysates were prepared
using a Pica Gene kit (Toyo Ink Co., Tokyo, Japan),
and the light intensities were measured using a lu-
minometer.
3. Results
3.1. E¡ects of TNFK, DEX and IL-4 on the
expression of MMP-9 in oral SCC cells
In order to examine the ability of oral SCC to
produce MMP-9, seven cell lines derived from oral
SCC were cultured and treated for 24 h with or with-
out TNFK. Both gelatin zymography and Western
blot analysis of conditioned media showed that all
cell lines were able to produce a large amount of the
proenzyme form of MMP-9 (proMMP-9), which has
a molecular size of 92 kDa, by stimulation with
TNFK while some cell lines spontaneously secreted
proMMP-9 even in the absence of TNFK (Fig.
1A,B). All cell lines constitutively secreted pro
MMP-2 (68 kDa) which was not enhanced by
TNFK treatment. Among them, a cell line, SAS,
was further examined since it was the highest res-
ponder of the seven cell lines to TNFK in expressing
proMMP-9.
SAS cells were able to migrate through a gelatin-
Fig. 2. E¡ect of MMP inhibitor on the TNFK-induced migra-
tion of SCC cells. SAS cells (3U105 cells) were inoculated onto
the gelatin-coated membrane of a culture insert in serum-free
DMEM. While 100 ng/ml of TNFK was added into the lower
chamber, 10 WM of MMP inhibitor KB-R8301 or its analog
KB-R8845 was put into both the lower and upper chambers.
After 24 h, the cells, which had migrated to the lower surface
of the membrane, were ¢xed, stained and counted under a
microscope, as described in Section 2.
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coated membrane from the upper side to the lower
side after they were inoculated on the upper side of
the membrane and stimulated by TNFK (Fig. 2).
This TNFK-induced migration was blocked by a hy-
droxamic acid-based MMP inhibitor KB-R8301, but
not by its non-active analogue KB-R8845, suggesting
that MMPs are involved in this migration (Fig. 2).
At least during the 48 h culture period, neither KB-
R8301 or KB-R8845 had any e¡ect on cell viability,
which was checked by trypan blue exclusion.
MMP-9 seemed to be one of the migration-in-
volved MMPs targeted by the MMP inhibitor since
SAS cells produced a large amount of MMP-9 (Fig.
1). Fig. 1 also indicates that TNFK induced an active
MMP-2 (62 kDa) in SAS cells. We focused on the
expression of MMP-9, rather than MMP-2, of SAS
cells in the following studies because the secreted
levels of MMP-9 were much higher than those of
MMP-2. Since MMP-9 was thought to be a key mol-
ecule in tumor invasion, we explored the physiolog-
ical hormones or cytokines regulating MMP-9 syn-
thesis in tumor cells. It was found that two
immunosuppressive agents, DEX and IL-4, signi¢-
cantly inhibited the protein production and gene ex-
pression of proMMP-9 (Fig. 3A,B).
3.2. Inhibition of MMP-9 activation and
uPA expression by DEX and IL-4
In order to proteolyze its substrate matrices,
proMMP-9 must change to its active form. In our
experimental system, the longer treatment of SAS
cells with TNFK for 48 h revealed gelatinase activity
with a molecular size of 84 kDa, which corresponds
to that of active MMP-9, which was generated by
treatment with p-aminophenylmercuric acetate
(APMA), in the gelatin zymography (Fig. 3C). This
conversion from proMMP-9 to active MMP-9 may
be partly due to plasmin, a serine protease, since the
addition of plasmin into cultures induced the same
size of gelatinase (84 kDa) as active MMP-9 whose
production was inhibited by aprotinin, a serine pro-
Fig. 3. Inhibition of the expression and activation of MMP-9 by DEX and IL-4. (A) E¡ects of DEX and IL-4 on the proMMP-9 pro-
duction. SAS cells were incubated in serum-free DMEM for 24 h with or without TNFK (100 ng/ml). DEX (100 nM) or IL-4 (10 ng/
ml) was added 1 h prior to TNFK stimulation. The resulting conditioned media were analyzed by gelatin zymography. (B) E¡ects of
DEX and IL-4 on the expression of proMMP-9. Total RNA was extracted from con£uent SAS cells, which were treated with or with-
out TNFK (100 ng/ml) for 6 h. DEX or IL-4 was added to cultures 1 h prior to TNFK treatment. The expression of MMP-9 was ex-
amined by RT^PCR. (C) Inhibition of active MMP-9 induction by DEX and IL-4. SAS cells were incubated in serum-free DMEM
for 24 h or 48 h with TNFK (100 ng/ml). Plasmin (10 Wg/ml) was added to the culture media together with TNFK, in the presence or
absence of aprotinin (5 Wg/ml) or leupeptin (1 WM). In lanes 8^10, SAS cells were treated with TNFK and plasminogen (20 Wg/ml) for
the ¢rst 24 h, followed by treatment with vehicle, DEX or IL-4 for another 24 h. Lane 12 shows a positive control of active MMP-9
where proMMP-9 was treated with 2 mM of p-aminophenylmercuric acetate (APMA) for 1 h. The resulting conditioned media were
analyzed by gelatin zymography.
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tease inhibitor (Fig. 3C). Interestingly, DEX and IL-
4 also inhibited the induction of active MMP-9 in the
conditioned medium of SAS cells treated with TNFK
for 48 h (Fig. 3C).
Fig. 3C also indicates that the addition of plasmi-
nogen into cultures enhanced the induction of active
MMP-9, suggesting that SAS cells expressed plasmi-
nogen activator (PA) which can convert plasminogen
to plasmin. Again, the plasminogen-mediated induc-
tion of active MMP-9 was inhibited by DEX or IL-4
treatment, implying that DEX or IL-4 inhibits the
production of PA in tumors. Because it is known
that uPA, but not tissue type PA, plays a role in
some tumors, we then examined the expressions of
uPA in SAS cells. As a result, we found that TNFK
led SAS cells to express uPA in both levels of protein
and mRNA (Fig. 4A,B). Corresponding to the in-
crease in uPA synthesis, the proteolytic activity of
uPA also increased after TNFK treatment (Fig.
4C). DEX and IL-4 suppressed all the increased lev-
els of protein, mRNA and proteolytic activity of
uPA (Fig. 4). It is plausible that DEX and IL-4 pre-
vent the activation of proMMP-9 through the inhi-
bition of uPA synthesis.
3.3. E¡ects of DEX and IL-4 on the TNFK receptor
levels
To investigate the mechanisms by which DEX and
IL-4 inhibit TNFK-induced expressions of MMP-9
and uPA, we ¢rst examined the e¡ects of DEX and
IL-4 on the cell surface levels of TNFK receptors
(TNF-R). Analysis with £ow cytometry demon-
strated that SAS cells expressed TNF-R1, but not
TNF-R2, whose levels were not decreased by DEX
and IL-4 (Fig. 5), suggesting that DEX and IL-4 may
block the post-receptoral signaling pathway.
Glucocorticoid receptor (GR) and IL-4 receptor K
chain were detected in SAS cells by Western blot and
RT^PCR, respectively (data not shown). TNFK,
DEX, IL-4 and their combinations had no e¡ects
on the viability of SAS cells and the other SCC cell
Fig. 4. Inhibition of uPA expression by DEX and IL-4 in SCC cells. (A) Western blot analysis. SAS cells were incubated in serum-
free DMEM for 24 h in the absence or presence of TNFK (100 ng/ml). DEX (100 nM) or IL-4 (10 ng/ml) was added into cultures 1 h
prior to TNFK stimulation. The presence of uPA in the conditioned media was analyzed by Western blotting. (B) Northern blot anal-
ysis. Total RNA was extracted from SAS cells, which were treated with TNFK (100 ng/ml) for 6 h. DEX or IL-4 was added to cul-
tures 1 h prior to TNFK stimulation. The induction of uPA mRNA was examined by Northern blotting. (C) Proteolytic activity. Fifty
Wl of the conditioned media, which was collected as described in A, was incubated with plasmin substrate, S-2251 (1.5 mM) and plas-
minogen (60 Wg/ml) at 37‡C. The uPA activity was estimated as the release of paranitroaniline from S-2251 by measuring the absor-
bance at 405 nm. The absorbance of the control sample (vehicle) is expressed as 1.0 in the vertical axis of this ¢gure.
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lines, which were examined by trypan blue exclusion
and MTT assay (data not shown).
3.4. Suppressive e¡ect of DEX and IL-4 on the
activation of a transcription factor NF-UB in
SCC cells
Since the target genes whose transcription is acti-
vated by NF-UB include the genes of MMP-9 and
uPA [12,13], we then investigated the e¡ects of
DEX and IL-4 on the TNFK-mediated activation
of NF-UB. The EMSAs indicated that TNFK acti-
vated NF-UB of SAS cells and that DEX as well as
IL-4 partially suppressed the NF-UB activation in the
TNFK-stimulated SAS cells (Fig. 6A). Furthermore,
investigations employing NF-UB-dependent lucifer-
ase reporter construct demonstrated that the NF-
UB-dependent transactivation was also partially sup-
pressed by DEX and IL-4 in SAS cells (Fig. 6B).
DEX and IL-4 seemed to inhibit the expression
and uPA-mediated activation of MMP-9 through
NF-UB inhibition.
3.5. E¡ects of DEX and IL-4 on the expression of
IUBK
Next, we investigated how NF-UB was inhibited by
DEX and IL-4. Because DEX has been reported to
induce IUBK synthesis to inhibit the NF-UB activity
of HeLa cells and T cells [21,22], the e¡ects of DEX
and IL-4 on the expression of IUBK were examined in
SAS cells. As shown in Fig. 7A, mRNA of IUBK was
strongly induced by treatment with TNFK. This ex-
pression of the IUBK gene appeared to be mediated
by TNFK-activated NF-UB since the promoter region
of the IUBK gene contains the NF-UB-binding se-
quence [23]. The NF-UB-dependent induction of
IUBK is thought to function as negative feedback to
halt the action of NF-UB. Interestingly, DEX seemed
to augment the expression of IUBK triggered by
Fig. 5. Flow cytometric analysis of TNFK receptor expressed on SCC cells. After treatment with vehicle, TNFK, DEX or IL-4 for 6 h,
single cell suspensions of SAS cells were prepared and stained with non-immune serum, anti-TNF-R1 or anti-TNF-R2 antibody for
30 min at 4‡C. Anti-L1 integrin antibody was also used as a positive control. The number of cells expressing TNF-R1 or TNF-R2
was determined by £ow cytometry as described in Section 2.
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TNFK in SAS cells whereas DEX alone induced only
a slight expression of IUBK. In addition, DEX-pre-
treatment seemed to promote the resynthesis of IUBK
which was once degraded 15 min after TNFK stim-
ulation (Fig. 7B). This suggests that DEX-mediated
upregulation of IUBK suppresses NF-UB-transacti-
vated expression of MMP-9 and uPA, explaining
the partial, but not complete, inhibition of NF-UB
by DEX. However, IL-4 had no e¡ects on IUBK in-
duction (data not shown).
4. Discussion
Glucocorticoids or their synthetic analogues have
been used clinically as potent anti-in£ammatory and
immunosuppressive drugs, but the molecular mecha-
nism by which they worked has been poorly under-
stood. Recently, it has been found that a synthetic
glucocorticoid, DEX, suppressed NF-UB activation,
thus explaining its immunosuppressive function
[21,22]. Furthermore, the present study indicates
that DEX may suppress not only in£ammation, but
also tumor invasion through NF-UB inhibition.
There have been two models to explain the mech-
anisms of NF-UB suppression by glucocorticoids.
The ¢rst model is based on the ¢nding that gluco-
corticoids inhibit NF-UB activity via the increased
induction of IUBK [21,22]. The second model pro-
poses that glucocorticoid receptor (GR) directly
binds to the p65 subunit of NF-UB to mask the
transactivation domain of p65 [24]. In the present
study, DEX and TNFK synergistically increased the
expression of IUBK in SCC cells while DEX alone
had little e¡ect on IUBK induction. However, we
could neither immunoprecipitate GR protein with
anti-p65 antibody nor p65 protein with anti-GR anti-
body (data not shown). Thus, the former model cor-
responds to our data. DEX may upregulate IUBK
expression most e⁄ciently under conditions where
NF-UB is already activated by TNFK.
It remains unknown how IL-4 inhibits NF-UB ac-
Fig. 6. Suppression of NF-UB by DEX and IL-4 in SCC cells. (A) EMSA. SAS cells were pretreated with vehicle, DEX (100 nM) or
IL-4 (10 ng/ml) for 1 h, and then treated with TNFK (100 ng/ml) for 15 min. After treatment, the nuclear extracts were prepared
from the cells as described in Section 2. The DNA binding activity of NF-UB was measured by EMSAs. The arrow indicates the posi-
tion of NF-UB (p65/p50 heterodimer). (B) Luciferase assay. SAS cells (1U106) were transfected with NF-UB-dependent luciferase re-
porter construct as described in Section 2, then stimulated by TNFK (100 ng/ml) with or without pretreatment of DEX (100 nM) or
IL-4 (10 ng/ml). Luciferase activity in the cells was measured by luminometer. The absorbance of the control sample (vehicle) is ex-
pressed as 1.0 in the vertical axis of this ¢gure.
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tivation. IL-4 and interleukin-10 (IL-10) are immu-
nosuppressive cytokines released from Th2 type T
cells. Wang et al. demonstrated that IL-10, but not
IL-4, suppressed NF-UB activation in lipopolysac-
charide-stimulated monocytes [25]. The mechanism
of NF-UB suppression was not determined in their
report. In contrast, our data showed that IL-4 was
able to inhibit NF-UB activation and MMP-9 pro-
duction in the TNFK-stimulated SCC cells while IL-
10 had no e¡ects (data not shown).
IUBK is reported to be tyrosine-phosphorylated,
which prevents its serine-phosphorylation by IUB ki-
nases [26]. Tyrosine-phosphorylated IUBK becomes
resistant to proteasomal proteolysis, resulting in the
inactivation of NF-UB [26]. Although IL-4 can acti-
vate such tyrosine kinases as JAK-1, the TNFK-trig-
gered proteolysis of IUBK was not prevented by IL-4
and any retarded bands of phosphorylated IUBK
were not detected in the EMSAs. Further investiga-
tions are required to determine the IL-4 mechanisms.
The molecular events occurring in tumor invasion
are known to resemble those seen in such wound
healing process as extracellular matrix degradation,
which is triggered by in£ammation [15]. In£amma-
tory and immunological reactions, therefore, seem to
be profoundly involved in such tumor behaviors as
invasion and metastasis. Moreover, the host defense
mechanism against cancer leads macrophages to in-
¢ltrate tumors. The tumor associated macrophages
were reported to release TNFK and other angiogenic
factors to activate NF-UB in vascular endothelial
cells and promote the tumor angiogenesis resulting
in metastasis and poor prognosis [27]. Therefore,
such anti-NF-UB therapy as the use of anti-in£am-
matory factors may contribute to the reduction of
tumor invasiveness.
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